The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma.
Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA.
Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA, USA.
- Published Article
Blood and lymphatic cancer : targets and therapy
- Publication Date
Jan 01, 2019
The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/refractory patients. Treatment indications for the antibody-drug conjugate have been expanded from the previously treated population to include maintenance therapy after autologous stem cell transplantation and recently, combination with chemotherapy in newly diagnosed advanced stage patients. This article will review the evolution of BV in classical Hodgkin lymphoma, detailing the studies that led to the approved indications and discussion of recent trials in combination with chemotherapy and immunotherapy. © 2019 Lai et al.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 01/04/2021 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/31849558